Effectiveness and safety of enfortumab vedotin and pembrolizumab in a real-world patient population with urothelial carcinoma: results from a multi-institutional cohort (GUARDIANS).

Zschäbitz S, Bhatti I, Casuscelli J, Pachmayr LO, Büttner T, Elegeert T, Holzwarth N, Rodler S, Hennig M, Rinderknecht E, Dib M, Schlack K, Darr C, Volk AL, Schmucker P, Zengerling F, Paffenholz P, Heil J, Erne E, Mandal S

Year

2026

Journal

Cancer immunology, immunotherapy : CII